Larimar Therapeutics, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
10.50
|
|
Average Rating
|
4.40
|
|
# Strong Buys
|
3
|
|
# Buys
|
1
|
|
# Holds
|
1
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-0.42
|
-0.37
|
0.05
|
11.90%
|
|
2022-06-30
|
-0.57
|
-0.47
|
0.10
|
17.54%
|
|
2022-03-31
|
-0.51
|
-0.49
|
0.02
|
3.92%
|
|
2021-12-31
|
-0.72
|
-0.50
|
0.22
|
30.56%
|
|
2021-09-30
|
-0.64
|
-0.92
|
-0.28
|
-43.75%
|
|
2021-06-30
|
-0.75
|
-0.79
|
-0.04
|
-5.33%
|
|
2021-03-31
|
-0.86
|
-0.76
|
0.10
|
11.63%
|
|
2020-12-31
|
-0.70
|
-0.89
|
-0.19
|
-27.14%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-1.33
|
|
2021-12-31
|
-2.97
|
|
2020-12-31
|
-3.94
|
|
2019-12-31
|
-14.52
|
|
2018-12-31
|
-17.02
|
|
2017-12-31
|
-1.91
|
|
2016-12-31
|
-2.12
|
|
2015-12-31
|
-2.77
|
|
2014-12-31
|
-3.89
|